Abituzumab Combined with Cetuximab Plus Irinotecan Versus Cetuximab Plus Irinotecan Alone, as Second-Line Treatment for Patients with KRAS Wild-Type Metastatic Colorectal Cancer: The Poseidon Phase I/Randomized Phase II Trial
Titel:
Abituzumab Combined with Cetuximab Plus Irinotecan Versus Cetuximab Plus Irinotecan Alone, as Second-Line Treatment for Patients with KRAS Wild-Type Metastatic Colorectal Cancer: The Poseidon Phase I/Randomized Phase II Trial
Auteur:
Elez, E. Kocáková, I. Höhler, T. Martens, U. Bokemeyer, C. Van Cutsem, E. Melichar, B. Smakal, M. Cso˝szi, T. Vyushkov, D. Topuzov, E. Orlova, R. Tjulandin, S. Rivera, F. Straub, J. Bruns, R. Quaratino, S. Tabernero, J.